Table 1 Juvenile eosinophilic fasciitis cohort patient characteristics. Bolded laboratory values are elevated above reference ranges
From: Juvenile eosinophilic fasciitis: a single center case series
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
|---|---|---|---|---|---|---|
Sex | M | F | F | F | F | F |
Race | White | White | White | White | White | Black |
Ethnicity | Non-Hispanic | Hispanic | Hispanic | Non-Hispanic | Non-Hispanic | Non-Hispanic |
Age at diagnosis (years) | 14 | 4 | 10 | 12 | 16 | 16 |
Current age (years) | 28 | 14 | 15 | 15 | 18 | 18 |
Symptom onset to diagnosis (months) | 12 | 12 | 6 | 12 | < 1 | 1 |
Follow up duration (months) | 58 | 123 | 52 | 28 | 23 | 14 |
Other medical conditions Prior to EF diagnosis At or after EF diagnosis | Localized scleroderma | Localized scleroderma, JIA | Localized scleroderma, JIA | 22q11.23 deletion, Epilepsy JIA | Hashimoto thyroiditis, environmental and food allergies genetic factor XI deficiency | None Acquired hemophilia A |
Diagnosis labs AEC (cells/uL, ref: 20–320) IgG (mg/dL, ref: 641–1353) CK (U/L, ref: > 295) Aldolase (U/L, ref: 3.3 – 9.7) ESR (mm/hr, ref: < 1–20) | 700 1990 209 7.1 14 | 8206 1888 21 12 25 | 1390 2100 33 11.4 75 | 865 2221 20 17.3 6 | 2130 1330 28 15.6 21 | 390 1720 9 34 |
Immunomodulation medications | CS MTX HCQ | CS MTX HCQ IVIG TOCI | CS MTX HCQ IVIG RTX TOCI | CS MTX MMF | CS MTX HCQ IVIG | CS MTX RTX |
Current rheumatology medications | None | TOCI | HCQ | MTX, MMF | HCQ, MTX | MTX |
History of recurrence of EF | No | Yes | Yes | No | No | Yes |